We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Drager Medical

Drager Medical manufactures anesthesia workstations, medical ventilation, patient monitoring as well as neonatal care... read more Featured Products: More products

Download Mobile App




New Jaundice Meter Helps Protect Development of Infants

By LabMedica International staff writers
Posted on 30 Oct 2013
A new, noninvasive meter provides multiple advantages compared to currently used methods for diagnosing jaundice in infants.

More than half of healthy newborn infants have bilirubin levels that are too high. More...
Dräger (Lübeck, Germany) now offers the Jaundice Meter JM-105 by which caregivers can noninvasively measure bilirubin levels in newborns as young as 24 weeks gestational age. Screening with this device can reduce or even eliminate painful, repeated blood-draws with possible long-term consequences particularly in young patients. A study of premature infants from the 24th week showed that repeated pain experiences can affect the maturation of neuronal structures which may adversely affect brain and emotional development. Instead of the often used approach of testing infants for total serum bilirubin (TSB) (via blood-draws from the heel), jaundice can be diagnosed reliably and painlessly with transcutaneous bilirubin screening (TcB). Studies have shown that noninvasive measurement results correlate with bilirubin levels collected by venipuncture. Study results have also shown that TcB measurements were comparable with TSB values for premature babies from the 24th week gestational age.

"Until now, jaundice screening as early as the 24th week gestational age was not yet approved for use in many countries. The JM-105 contributes to reducing painful examinations for these tiny patients, thereby supporting their development," said Inken Schroeter, product manager at Dräger.

The Dräger JM-105 jaundice meter also simplifies measurement as well as reduces monetary and environmental cost by much reducing consumables compared to blood-draw based methods. The measurement is taken by gently pressing the sensor on the infants's forehead or sternum. All device functions can be controlled using a color touch screen. The sensor is easily cleaned with rubbing alcohol before every screening process. Since the device is reusable, usual disposable products are no longer needed.

Paper use and manually entering or transferring measured values are things of the past with the JM-105 – all readings and data are stored in the device and can be transferred electronically to the clinic's PDMS (Patient Data Management System) by placing the device in a docking station and using a USB connection. The JM-105 enables data transfer via the interface standard HL 7 (Health Level 7).

The JM-105 stores up to 100 readings in its patient history. A nurse can label abnormal values by attaching a flag symbol to a patient’s measurement so the clinical team can later locate the patient more quickly for further assessment. The device configuration setting can be adjusted to take a single measurement or up to five measurements for an average value. This means the meter can identify newborns at increased risk for hyperbilirubinemia with higher accuracy.

Dräger and the European Society of Intensive Care Medicine (ESICM) have awarded the 2013 “Bernhard Dräger Award” to Evangelia Akoumianaki, who investigates the causes for respiration muscle contractions during mechanical ventilation (reverse triggering) of sedated intensive care patients. She will also explore whether this reverse triggering can be detected noninvasively.

Related Links:

Dräger



Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
STI Test
RIDA GENE STI Mycoplasma Panel
New
Chlamydia Pneumoniae Test
Chlamydia Pneumoniae (CP) Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.